← Back

Novo Holdings

International · active in EuropeMulti-stage fund Seed Series-A Above Series A
Cheque range
£5M – £50M
Stages
Seed, Series A, Above Series A
Avg deals / year
8.5
Leads rounds
Yes
HQ
London
Fund type
Multi-stage fund

01 · Thesis & focus

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations.

Sectors (1)

02 · Recent publicly announced deals

OMass Therapeutics 🇬🇧 Series C · Oct 2026 · $310M First-cheque stage announcement ↗ site ↗

Oxford spinout developing small-molecule drugs for endocrine and immune diseases.

Founders: Idlir L., Jonathan H.
Breye Therapeutics 🇩🇰 Series A · Oct 2026 · €67.5M First-cheque stage announcement ↗

Copenhagen clinical-stage biotech developing oral therapies for retinal diseases

AnaCardio 🇸🇪 Series B · Oct 2026 · €62.5M First-cheque stage announcement ↗

Stockholm biotech developing an oral drug for advanced heart failure

Founders: Lars L.

03 · Similar firms

Raising? See which European funds fit your round →